此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery (SPAR-Breast)

2026年11月10日 更新者:Mahidol University

Dosimetric Comparison of Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery: A Prospective Paired Study

This study aims to compare two positions used for whole-breast radiation therapy in Thai women who have undergone breast-conserving surgery: lying on the back (supine) and lying face down (prone).

Radiation therapy after breast-conserving surgery helps reduce the risk of breast cancer returning. However, some radiation may reach nearby organs, particularly the heart and lungs. The position used during treatment may affect how much radiation these organs receive.

In this study, 24 women will undergo radiation treatment planning CT scans in both the supine and prone positions. Researchers will create a radiation treatment plan for each position and compare how well the plans cover the breast while minimizing radiation exposure to the heart and lungs. Each participant will receive actual radiation treatment in only one of the two positions, selected based on treatment planning results and clinical suitability.

The study will also assess patient comfort, positioning accuracy, treatment setup time, and treatment-related side effects.

The findings may help identify which patients are more likely to benefit from prone positioning and support individualized breast radiation treatment planning in Thai women.

研究概览

详细说明

This is a prospective paired within-patient dosimetric study comparing supine and prone whole-breast radiotherapy in Thai women after breast-conserving surgery.

Each participant will undergo CT simulation in both the supine and prone positions. A three-dimensional conformal radiotherapy plan will be generated for each position using the same planning approach. The two plans will first be evaluated for acceptable target coverage. They will then be compared according to radiation exposure to organs at risk, with primary consideration given to the heart and ipsilateral lung and secondary consideration given to the contralateral lung and contralateral breast.

The treatment position used for actual radiotherapy will be selected using a predefined plan-comparison algorithm based on target coverage and organ-at-risk dose criteria. If both plans are otherwise comparable, patient preference may be used as a final decision factor. The participant will receive treatment in only one selected position.

The study will also explore whether anatomical characteristics, including chest wall and breast-related measurements, are associated with greater dosimetric benefit from prone positioning. Additional assessments include treatment setup time, positioning accuracy, patient comfort and preference, and treatment-related toxicity.

The study is intended to provide institution-specific data on individualized selection of breast radiotherapy position in Thai women rather than assuming that either supine or prone positioning is preferable for all patients.

研究类型

介入性

注册 (估计的)

24

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Histologically confirmed breast carcinoma or ductal carcinoma in situ (DCIS)
  • Status post breast-conserving surgery
  • Planned adjuvant breast-only radiotherapy
  • No indication for regional nodal irradiation
  • Preoperative breast size corresponding to bra cup A-B, defined by the patient's preoperative bra size or a bust-minus-underbust circumference difference of <14 cm
  • Age ≥18 years

Exclusion Criteria:

  • Planned treatment using Deep Inspiration Breath Hold (DIBH)
  • Bilateral breast cancer
  • Previous radiotherapy to the ipsilateral breast
  • Unable to tolerate either the prone or supine position
  • Breast volume >750 cm³
  • Pre-existing heart disease or lung disease
  • Active connective tissue disease
  • Pregnant or found to be pregnant

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Supine and Prone Whole-Breast Radiotherapy Planning

All participants will undergo CT simulation and treatment planning in both the supine and prone positions. The two plans will be compared for target coverage and radiation dose to organs at risk, including the heart and ipsilateral lung. Actual whole-breast radiotherapy will be delivered in only one selected position based on predefined plan-selection criteria and clinical suitability.

Participants will undergo CT simulation in both supine and prone positions after breast-conserving surgery. Whole-breast radiotherapy plans will be generated for both positions using 3-dimensional conformal radiotherapy (3D-CRT). Target coverage and organ-at-risk dosimetric parameters will be compared between the two plans. The treatment position will be selected according to predefined target coverage and organ-at-risk criteria. Participants will receive actual radiotherapy in the selected position only. The prescribed whole-breast dose is 40 Gy in 15 fractions, with a simultaneous integrated boost to 48 Gy in selected patients.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Mean Heart Dose in Supine Versus Prone Treatment Plans
大体时间:within 4 weeks after both CT simulations

Mean radiation dose to the heart, measured in Gray (Gy), will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. The mean heart dose will be compared between the two positions while maintaining acceptable target coverage.

within 4 weeks after both CT simulations
Mean Ipsilateral Lung Dose in Supine Versus Prone Treatment Plans
大体时间:within 4 weeks after both CT simulations

Radiation dose to the lung on the same side as the treated breast will be assessed from the dose-volume histogram for both supine and prone treatment plans. Dosimetric parameters will include mean ipsilateral lung dose, and will be compared within the same participant while maintaining acceptable target coverage.

within 4 weeks after both CT simulations

次要结果测量

结果测量
措施说明
大体时间
PTV_Eval V95 in Supine Versus Prone Treatment Plans
大体时间:within 4 weeks after both CT simulations

PTV_Eval V95, defined as the percentage of PTV_Eval receiving at least 95% of the prescribed dose, will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. PTV_Eval V95 will be compared between the two positions. The unit of measure is percentage (%).

within 4 weeks after both CT simulations
Treatment time from initial setup to treatment completion
大体时间:within 4 weeks after treatment completion

Time required for patient positioning and setup until treatment is completed will be recorded and compared between the supine and prone positions. Time will be reported in minutes.

within 4 weeks after treatment completion
translational X Positioning Accuracy
大体时间:within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational X axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
translational Y Positioning Accuracy
大体时间:within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Y axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
translational Z Positioning Accuracy
大体时间:within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Z axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
Patient Satisfaction Score
大体时间:within 1 hours after both CT simulations, and within 1 hours after treatment completion

Patient satisfaction will be assessed using a study-specific questionnaire. Comfort and satisfaction will be rated using a 5-point Likert scale ranging from 1 to 5, with higher scores indicating greater comfort and satisfaction with the position.

within 1 hours after both CT simulations, and within 1 hours after treatment completion
Radiation Therapist Satisfaction
大体时间:within 1 hours after treatment completion

Radiation therapist satisfaction with patient positioning will be assessed using a study-specific 5-point Likert satisfaction scale for the supine and prone positions. Scores range from 1 to 5, with higher scores indicating greater radiation therapist satisfaction with the positioning technique.

within 1 hours after treatment completion
Acute Skin Toxicity using CTCAE Version 5.0 graing scale
大体时间:Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion

Acute radiation-related skin toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Radiation dermatitis will be graded from Grade 0 to Grade 5, with higher grades indicating greater severity of skin toxicity.

Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Tanun Jitwatcharakomol, MD、Mahidol University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2026年10月28日

首先提交符合 QC 标准的

2026年11月10日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅